{
    "rcn": "207443",
    "acronym": "IMMUNOSABR",
    "topics": "SC1-PM-09-2016",
    "title": "Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer",
    "startDate": "01/01/2017",
    "endDate": "31/12/2022",
    "objective": "IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 (watch our animation explaining the concept at https://youtu.be/6wDE6RkrikA).\n\nPalliative treatment is the current standard of care for patients with metastatic non small cell lung cancer (NSCLC), unless there is an actionable mutation. By using the concept of limited metastatic disease (?10 sites, WHO 0-1: ìoligo\\î) we aim to develop a therapy with curative intent. IMMUNOSABR will gather evidence for the clinical efficacy of our bi-modal treatment strategy in a multicentre randomised phase II study (clinicaltrials.gov no. NCT02735850) in patients with limited metastatic NSCLC.  \n\nIMMUNOSABR is complemented by two strong biomarker work packages which focus on developing an ambitious personalised biomarker strategy, to identify patients who can benefit from the novel treatment strategy. This includes promising non-invasive imaging techniques and state-of-the-art immunological monitoring approaches on tumour tissue and blood. IMMUNOSABR will spur further development of L19-IL2 as a commercial drug and translate the bi-modal treatment strategy towards clinical implementation.",
    "totalCost": "7951268,5",
    "ecMaxContribution": "5994176,25",
    "coordinator": "UNIVERSITEIT MAASTRICHT",
    "coordinatorCountry": "NL",
    "participants": "HEALTH INNOVATION VENTURES BV;STICHTING KATHOLIEKE UNIVERSITEIT;CENTRE OSCAR LAMBRET;Universitair Ziekenhuis Gent;CLINIQUES UNIVERSITAIRES SAINT-LUC;ACADEMISCH ZIEKENHUIS MAASTRICHT;PHILOGEN SPA;STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS;EUROPEAN CANCER PATIENT COALITION;DANMARKS TEKNISKE UNIVERSITET;EBERHARD KARLS UNIVERSITAET TUEBINGEN;University College London;KATHOLIEKE UNIVERSITEIT LEUVEN;PT THERAGNOSTIC BV;UNIVERSITA CATTOLICA DEL SACRO CUORE;TECHNISCHE UNIVERSITAET DRESDEN",
    "participantCountries": "NL;FR;BE;IT;DK;DE;UK",
    "projectParticipants": {
        "999576562": {
            "orgId": "999576562",
            "orgName": "ACADEMISCH ZIEKENHUIS MAASTRICHT",
            "ecContrib": 388581
        },
        "998753226": {
            "orgId": "998753226",
            "orgName": "CLINIQUES UNIVERSITAIRES SAINT-LUC",
            "ecContrib": 157231
        },
        "999984738": {
            "orgId": "999984738",
            "orgName": "STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS",
            "ecContrib": 157231
        },
        "999975911": {
            "orgId": "999975911",
            "orgName": "UNIVERSITEIT MAASTRICHT",
            "ecContrib": 1093575
        },
        "999915771": {
            "orgId": "999915771",
            "orgName": "UNIVERSITA CATTOLICA DEL SACRO CUORE",
            "ecContrib": 157231
        },
        "999992110": {
            "orgId": "999992110",
            "orgName": "STICHTING KATHOLIEKE UNIVERSITEIT",
            "ecContrib": 157231
        },
        "986974031": {
            "orgId": "986974031",
            "orgName": "PHILOGEN SPA",
            "ecContrib": 726250
        },
        "999990655": {
            "orgId": "999990655",
            "orgName": "DANMARKS TEKNISKE UNIVERSITET",
            "ecContrib": 1078408
        },
        "941171795": {
            "orgId": "941171795",
            "orgName": "PT THERAGNOSTIC BV",
            "ecContrib": 312500
        },
        "999897729": {
            "orgId": "999897729",
            "orgName": "TECHNISCHE UNIVERSITAET DRESDEN",
            "ecContrib": 207231
        },
        "984738375": {
            "orgId": "984738375",
            "orgName": "Universitair Ziekenhuis Gent",
            "ecContrib": 157231
        },
        "999975620": {
            "orgId": "999975620",
            "orgName": "UNIVERSITY COLLEGE LONDON",
            "ecContrib": 0
        },
        "984108263": {
            "orgId": "984108263",
            "orgName": "EUROPEAN CANCER PATIENT COALITION",
            "ecContrib": 95062
        },
        "938285657": {
            "orgId": "938285657",
            "orgName": "HEALTH INNOVATION VENTURES BV",
            "ecContrib": 434250
        },
        "992641935": {
            "orgId": "992641935",
            "orgName": "CENTRE OSCAR LAMBRET",
            "ecContrib": 157231
        },
        "999991916": {
            "orgId": "999991916",
            "orgName": "EBERHARD KARLS UNIVERSITAET TUEBINGEN",
            "ecContrib": 318850
        },
        "999991334": {
            "orgId": "999991334",
            "orgName": "KATHOLIEKE UNIVERSITEIT LEUVEN",
            "ecContrib": 238850
        }
    },
    "calculatedTotalContribution": 5836943
}